United States securities and exchange commission logo September 26, 2022 Steven Burden, Ph.D. Chief Executive Officer Facible BioDiagnostics, Inc. 366 SW 5th Ave, Ste. 104 Meridian, ID 83642 Re: Facible BioDiagnostics, Inc. Post-Qualification Amendment to Offering Statement on Form 1-A Filed September 20, 2022 File No. 024-11878 Dear Dr. Burden: This is to advise you that we do not intend to review your amendment. We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Nicholas Antaki